Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Uwe Blohmer J, Zahm DM, Jackisch C, Mackelenbergh MV, Thomalla J, Marmé F, Huober J, Müller V, Schem C, Müller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Denkert C, Seliger B.
Massa C, et al. Among authors: denkert c.
Clin Transl Med. 2024 Apr;14(4):e1617. doi: 10.1002/ctm2.1617.
Clin Transl Med. 2024.
PMID: 38664548
Free PMC article.
No abstract available.